Kajian klinikal Limfoma di Georgia
16 kajian untuk Limfoma sedang mencari peserta di lokasi di Georgia.
Bandar di Georgia
Teks kajian rasmi (Bahasa Inggeris)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Emory University Medical Center, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07192471A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Healthcare of Atlanta - Egleston Hospital, Atlanta
Mengambil pesertaFasa 1/2
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04094610Collection of Tissue Samples for Cancer Research
- Emory University, Atlanta
Mengambil pesertaKajian pemerhatian
2 Months · Semua jantina · Dikemas kini 16 Sep 2026 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Mengambil pesertaFasa 1/2
12 Months – 21 Years · Semua jantina · Dikemas kini 11 Sep 2026 · NCT04870944Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Atlanta, Newnan
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Augusta University Medical Center, Augusta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Winship Cancer Institute of Emory University, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northside Hospital, Atlanta
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Winship Cancer Institute of Emory University, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- Emory University Hospital, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jul 2026 · NCT07465835A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Healthcare of Atlanta - Egleston, Atlanta
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152Pilot Imaging Study of Leukemia
- Emory University, Atlanta
Mengambil pesertaFasa 1
Umur 4 hingga 80 · Semua jantina · Dikemas kini 23 Apr 2026 · NCT03633955A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Atlanta, Newnan
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06915246cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- North Georgia Health System, Gainesville
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.